SARASOTA, Fla., Feb. 13 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (“IBC”), a company committed to the principles of sustainable development by commercializing technologies that enable bio-friendly chemical production, announced today that it has appointed biotechnology veteran Gurinder Shahi, M.D., Ph.D., as its new Chief Technologist and Chairman of its Scientific Advisory Board.
Dr. Shahi has been dedicated to understanding market dynamics and is well known in the biotechnology sector. He brings to IBC a rich background in the business and science of molecular biochemistry, international health policy, and technology innovation management.
As Chief Technologist, Dr. Shahi’s responsibilities will include strategic oversight, direction and management of the company’s technology infrastructure, with staff and resources in the United Kingdom, the United States, and Asia, as well as the development of IBC’s commercial product pipeline. His focus will be on the implementation and execution of IBC’s existing proprietary technologies, as well as the acquisition and integration of synergistic new intellectual property and technology platforms. He will coordinate his efforts with the marketing and manufacturing teams to translate these opportunities into new IBC products and services, which will improve the company’s ability to create a sustainable competitive advantage, in particular the identification of new global market opportunities.
Dr. Shahi has played a key role in driving the development of several major international research and development initiatives, including the International Vaccine Institute and the Asia-Pacific International Molecular Biology Network (A-IMBN), for which he served as Executive Director/Coordinator. He has led biotechnology industry development in many parts of the world and serves as advisor to many leading international organizations, governments and foundations.
“Gurinder Shahi’s leadership in the technology arena is a perfect fit for IBC’s innovative biological chemical production system. He has a unique understanding of where this technology is moving and how it will impact the future,” said Ron Doran, president and Director of IBC. “Dr. Shahi is our franchise player. He is a respected, seasoned executive in the industrial biotechnology market. I am confident he will greatly assist in the successful execution of our business model and will bring important guidance to IBC technology and company operations.”
Dr. Shahi has authored over 50 articles, refereed journal papers, conference presentations and books, including the influential book “BioBusiness in Asia: How Asian Countries can Capitalize on the Life Science Revolution” (Pearson Prentice Hall, 2004). He has served as lead editor for “International Perspectives on Environment, Development and Health: Toward a Sustainable World” (GS Shahi, BS Levy, A Binger, T Kjellstrom and RS Lawrence, Springer Publishing Company, New York, 1997) and is currently working on completing a series of new books/analyses, including: “Global BioBusiness - A Primer,” “Global BioBusiness Hotspots,” and “Technology Innovation and World Change.”
Dr. Shahi received his M.D. and Ph.D. from the National University of Singapore and his M.P.H. from Harvard University. He is Chairman of BioEnterprise Asia and leads the Global BioBusiness Initiative at the Marshall School of Business, University of Southern California.
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a substantially lower environmental impact than traditional methods, and with a higher purity.
Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC will bring to market new and established chemicals that are in high demand for use in flavors, fragrances and fine chemicals, and pharmaceutical, agricultural, environmental and bio- energy applications.
IBC’s pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large commercial production levels.
IBC’s core intellectual property utilizes patented technologies exclusively licensed from Rice University and The University of Oxford. These technologies enable the biological production of over 15,000 commercially available chemicals, many of which are used in the flavor and fragrance industry.
The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and will seek to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable, biological-based solutions and related intellectual property patents.
For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words such as “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation’s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology Corporation
CONTACT: David West of Industrial Biotechnology Corporation,+1-941-925-2500
Web site: http://www.industrialbiotechnology.com/
